Foghorn Therapeutics Inc. Deferred Costs, Noncurrent
Foghorn Therapeutics Inc. (FHTX) had Deferred Costs, Noncurrent of $1.97 million as of 2020-09-30, per its 10-Q filed 2020-12-04.
Discontinued › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:DeferredCosts · last filed 2020-12-04
- 2020-09-30: Deferred Costs, Noncurrent $1.97M.
| Period end | Deferred Costs, Noncurrent |
|---|---|
| 2020-09-30 | $1.97M 10-Q · filed 2020-12-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |